Ann H. Partridge, MD, MPH: New Data on Pregnancy and Breast Cancer Treatment

Posted: Thursday, January 5, 2023

Ann H. Partridge, MD, MPH, of Dana-Farber Cancer Institute, discusses the importance of incorporating patient-centered reproductive health care in the treatment and follow-up of young women with breast cancer, in light of results from the POSITIVE trial. The study showed that a temporary interruption of endocrine therapy in women with hormone-responsive breast cancer in order to attempt pregnancy does not affect short-term disease outcomes. Dr. Partridge discusses the practical clinical considerations of pregnancy and cancer therapy and the plans for long-term follow-up.